25th week of 2009 patent applcation highlights part 38 |
Patent application number | Title | Published |
20090155186 | Compositions and methods for treating inflammatory conditions - The present invention relates to compositions containing signal transduction modulator compounds, to methods for treating or preventing inflammation, or promoting healthy joints, using the compounds and to kits for the same. | 2009-06-18 |
20090155187 | DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA - To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress. | 2009-06-18 |
20090155188 | MOUTH ENVIRONMENT WITH ORAL COMPOSITION - A solid oral composition for providing a mouthwash efficacious effect comprising a non-hygroscopic base, carbamide peroxide, a bacterial immobilizing and sulfur sequestration agent, and an optional antioxidant enzyme. | 2009-06-18 |
20090155189 | Preparations, Methods and Kits Useful for the Treatment of Cough - The invention relates to a respiratory preparation providing cough relief in a human comprising: a thickening agent; a benefit agent. Additionally, the invention relates to a method of providing cough relief in a human comprising: the steps of administering to a human a respiratory preparation comprising: a thickening agent; a benefit agent. | 2009-06-18 |
20090155190 | Tooth Whitening Compositions and Delivery Systems Therefor - Stain-removing oral compositions, such as gum compositions, are herein provided. The gum compositions include a film-forming agent, such as a fatty acid salt, in combination with an abrasive and a chelating agent. The fatty acid salt may be a salt derived from a hydroxy fatty acid. The chelating agent may be a polyphosphate and the abrasive may be a silica abrasive. | 2009-06-18 |
20090155191 | Use of chlorhexidine in the prevention of root caries - Topical application of a solution of the antimicrobial chlorhexidine to teeth, particularly including exposed root surfaces, prevents the destruction of exposed cementum and associated exposed enamel at the cementum-enamel junction on tooth root surfaces (root caries) and the inflammation of the gingival tissue. In a method of use, a topical solution containing 10% (w/v) chlorhexidine, 20% (w/v) Sumatra benzoin, and 70% (w/v) ethanol is applied to the appropriate area of the tooth surface, followed immediately by application of a sealant which is a solution containing 29% (w/v) medical-grade polyurethane in 49% (w/v) acetone and 22% (w/v) ethyl acetate. Application of the chlorhexidine and sealant to the tooth cementum and gingival margin of “at risk” older adult patients has significantly reduced the prevalence and incidence of root caries and gingival inflammation. | 2009-06-18 |
20090155192 | Antibacterial 5,5'-disubstituted 3,3' dialkoxy-2,2'-dihydroxy-1,1'-biphenyl - The invention provides an antiplaque oral composition that includes an orally acceptable carrier; and an antibacterially effective amount of a compound of structure (I) | 2009-06-18 |
20090155193 | Topical Bioadhesive Formulations - The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament. | 2009-06-18 |
20090155194 | ENHANCED PHOTOSTABILITY OF AVOBENZONE IN THE PRESENCE OF ZINC OXIDE USING PHOSPHATE-BASED EMULSIFIERS - The photostability of avobenzone in a sunscreen composition in the presence of zinc oxide is stabilized against photodegradation using phosphate-based emulsifiers. | 2009-06-18 |
20090155195 | Capsules - The present invention related to (micro-or nano-) capsules that have two different functional groups on the outer shell of the particles that allow deposition onto the textile surfaces (i.e. exhibit substantivity) and subsequent covalent bonding of the particles onto the textile (i.e. are reactive towards the fiber). | 2009-06-18 |
20090155196 | COSMETIC PREPARATION - A cosmetic preparation comprising an aqueous solution of a water-soluble iron salt dimer, said aqueous solution containing magnesium ion and calcium ion. | 2009-06-18 |
20090155197 | Goniochromic indicator for skin sealant - A skin sealant composition having a film former like cyanoacrylate and a goniochromic dye or pigment is provided. The addition of mica/metal oxide powders to the sealant formulation makes it possible to see where it has been applied, due to the mica/metal oxide's goniochromic (e.g. irridescent or pearlescent) appearance, and it is also still possible to view the underlying skin, especially from an angle at which the color is less apparent. Thus, mica/titanium dioxide or other goniochromic or light interfering particles may be used as an additive to allow for determination of complete coverage, while not significantly obscuring the incision site. | 2009-06-18 |
20090155198 | PROCESS FOR TREATING HAIR FIBERS USING POLYSILOXANE/POLYUREA - A process for treating hair fibers comprising: applying to the hair fibers at least one cosmetic composition comprising, in a cosmetically acceptable medium, at least one polysiloxane/polyurea block copolymer; and subsequently or simultaneously heating the hair fibers at a temperature ranging from 50 to 280° C. | 2009-06-18 |
20090155199 | Apparatus and methods for pain relief using ultrasound energized polymers - Method and device to create energized polymers that can be used for pain relief, comprised of an ultrasound system that ultrasonically energize polymers that can then be used to provide an analgesic effect. Ultrasound waves are delivered to a polymer through direct contact, through a coupling medium, or without contact in order to energize the polymer. Other energies such as such as UV, microwave, laser, electricity, RF, sun, light, magnetic/electromagnetic, et can also be used to energize the polymer. The energized polymer can be immediately placed on a user to provide an analgesic effect, or the energized polymer can be placed storage material and removed at a later time to be placed on a user to provide an analgesic effect. | 2009-06-18 |
20090155200 | Methods of promoting cartilage healing or cartilage integration - The present invention provides methods of promoting cartilage healing or integration that include reducing the effective concentration of lubricin found in the extracellular matrix that is in contact with cartilaginous tissue. | 2009-06-18 |
20090155201 | Alkylated poly(allylamine) polymers and methods of use - The invention relates to a method for removing bile salts from a patient in need thereof and compositions useful in the method. The method comprises administering to the patient a therapeutically effective amount of a salt of an alkylated and crosslinked polymer. The alkylated and crosslinked polymer salt comprises the reaction product of crosslinked polymers, or salts and copolymers thereof having amine containing repeat units, with at least one aliphatic alkylating agent. | 2009-06-18 |
20090155202 | DNA-BINDING POLYMERS - Methods and compositions are provided for forming complexes between dsDNA and novel DNA-binding polymers comprising N-terminal thiophene-containing moieties which exhibit selectivity for T-A base pairs. By appropriate choice of target sequences and DNA-binding polymers, complexes comprising polymer-DNA are obtained with high association constants. The formation of complexes can be used for identification of specific dsDNA sequences, for inhibiting gene transcription, and as a therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific genes. | 2009-06-18 |
20090155203 | THROMBOPOIETIN MIMETICS - Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | 2009-06-18 |
20090155204 | Methods for treating disorders involving monocytes - Methods for treating disorders involving monocytic activity by administering IL-15 antagonists that induce apoptosis of monocytes are disclosed. | 2009-06-18 |
20090155205 | HUMAN ANTIBODIES THAT BIND HUMAN TNFa - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K | 2009-06-18 |
20090155206 | Methods, Compositions and Articles of Manufacture for Contributing to the Treatment of Cancers - Methods, compositions and articles of manufacture for contributing to the treatment of cancers, including solid tumors, are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET | 2009-06-18 |
20090155207 | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders - Methods of treating, preventing or managing transverse myelitis, multiple sclerosis, and/or other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 2009-06-18 |
20090155208 | Methods and agents for modulating an immune response - This invention is directed to the targeting of proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule and methods of use thereof. Nucleic acids, vectors comprising the same, and compositions for targeting proteins or peptides of interest to an autophagosome, for their presentation on a major histocompatibility complex (MHC) class II molecule are disclosed as are methods of use thereof for stimulating or enhancing immune responses in a subject. | 2009-06-18 |
20090155209 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-06-18 |
20090155210 | OXIMYL HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-06-18 |
20090155211 | Methods and Compositions for the Treatment of Autoimmune Disorders Using Clofarabine - This invention relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing an autoimmune disorder comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, prodrug or metabolite thereof and an additional therapeutic agent to a patient in need of such treatment. | 2009-06-18 |
20090155212 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer - The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs. | 2009-06-18 |
20090155213 | LACTOBACILLUS ACIDOPHILUS NUCLEIC ACIDS AND USES THEREOF - NCFM nucleic acid molecules, polypeptides, fragments and variants thereof are provided in the current invention. In addition, fusion proteins, antigenic peptides, and antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells comprising the expression vectors. Methods for producing the polypeptides of the invention and methods for their use are further provided. | 2009-06-18 |
20090155214 | NOVEL BACTERIA AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME - An object of the present invention is to provide a means for imparting resistance against pathogenic fungal, pathogenic bacterial, or pathogenic viral disease to agriculturally useful plants. The present invention relates to a bacterium belonging to the genus | 2009-06-18 |
20090155215 | ENGINEERED ENZYMATICALLY ACTIVE BACTERIOPHAGE AND METHODS FOR DISPERSING BIOFILMS - The present invention is directed to engineered enzymatically active bacteriophages that are both capable of killing the bacteria by lysis and dispersing the bacterial biofilm because they have been also engineered to express biofilm-degrading enzymes, particularly dispersin B (DspB), an enzyme that hydrolyzes β-1,6-N-acetyl-D-glucosamine, a crucial adhesion molecule needed for biofilm formation and integrity in | 2009-06-18 |
20090155216 | Grafting Material and Agent for Improvement in bone Quality - The present invention has an object to provide a transplant material allowing systemic bone substance improvement to be realized by cell transplant. The present invention teaches to use a transplant material comprising a cell selected from the group consisting of an embryonic stem cell, a mesenchymal stem cell, an osteoblast cell, a preosteoblast, a chondrocyte and a cell having a capability of bone formation through systemic or topical administration for the improvement in bone quality. | 2009-06-18 |
20090155217 | Novel E. coli O157:H7 Bacteriophage and Uses Thereof - The present invention is directed to isolated bacteriophage having strong lytic activity against strains of | 2009-06-18 |
20090155218 | COMPOSITIONS AND METHODS FOR GROWTH OF EMBRYONIC STEM CELLS - The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with a TGFβ family member protein, an FGF family member protein, and/or nicotinamide, without using fibroblast feeder layers, conditioned media, or leukemia inhibitory factor. | 2009-06-18 |
20090155219 | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES - The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies. | 2009-06-18 |
20090155220 | Use of Bone-Marrow Derived Stem Cells to Treat Ischemia - Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue. | 2009-06-18 |
20090155221 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 2009-06-18 |
20090155222 | CELL CULTURE - There is provided a method of retarding differentiation of a biological cell, the method comprising culturing the cell in the presence of an inhibitor of E-cadherin activity. The method is particularly advantageous in retarding the differentiation of stem or progenitor cells, and allows suspension culture of such cells in a manner that enables large scale expansion of cell populations. There is also provided a stem or progenitor cell comprising a construct encoding an inhibitor of E-cadherin activity; and a cell culture medium, for use in the retardation of biological cell differentiation, comprising an inhibitor of E-cadherin activity. | 2009-06-18 |
20090155223 | CELL-BASED COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF THE NERVOUS SYSTEM - Disclosed herein are cell-based compositions for the treatment of conditions of the nervous system and methods for their use. In one embodiment, a cell-based composition comprises glial-restricted progenitors (GRPs) genetically modified to express a targeting ligand on their cell surface. Methods for the preparation of such cell-based compositions are disclosed. Also disclosed is a method for treating a subject suffering from a condition of the central nervous system by providing therapeutic cells (e.g., GRPs) through an intra-arterial route of administration. | 2009-06-18 |
20090155224 | Dimethyl amino ethyl ether psoralens and methods for their production and use - Water-soluble dimethyl amino ethyl ether psoralens useful in the treatment of proliferative skin disorders, microbial infections and diseases, disorders of the blood and bone marrow of mammals and in microbiocidal compositions for sterilization of blood and blood products and surgical implants and inhibition of microbial growth in industrial applications are provided. | 2009-06-18 |
20090155225 | USES AND ISOLATION OF VERY SMALL OF EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 2009-06-18 |
20090155226 | Regenerative Dot cells - Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood, and bone marrow. The cells are characterized as expressing one or more markers selected from E-cadherin, integrin β1, CXCR4, CD90 and CD34, and may be selected on the basis of such expression patterns. | 2009-06-18 |
20090155227 | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy. | 2009-06-18 |
20090155228 | COMPOUNDS, KITS AND METHODS FOR CONFERRING CYTOPROTECTION - hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided. | 2009-06-18 |
20090155229 | CHONDROCYTE-BASED IMPLANT FOR THE DELIVERY OF THERAPEUTIC AGENTS - The present invention relates in general to chondrocyte based explants and implants of genetically engineered chondrocytes and in particular, to the delivery of peptides, proteins and RNAi molecules to a mammalian subject using a genetically modified chondrocyte-based mass. In one embodiment the genetically modified chondrocyte-based mass is provided as a chondrocyte pellet. | 2009-06-18 |
20090155230 | Novel genes and markers in essential arterial hypertension - The present invention relates to previously unknown disease associations between various genes, loci and biomarkers and essential hypertension. The detection of these biomarkers provides novel in vitro methods and test kits which can be used as an aid when making risk assessment, molecular diagnosis or prognosis of HT or a HT related condition. The disclosed methods and test kits do not require interaction with the body of a subject during the biomarker detection. Instead the methods and test kits are for in vitro use (e.g. in a clinical laboratory) and typically biological samples for the biomarker analyses using a method or a test kit of this invention have been collected earlier in a different place. In addition the biomarkers provide methods and systems for identifying novel agents for preventing, treating and/or reducing risk of HT or a HT related condition. The HT associated genes can be used to develop novel therapies for prevention and/or treatment of essential hypertension. | 2009-06-18 |
20090155231 | Compositions and Methods for Treatment of Neoplastic Disease - The present invention comprises the use of sickle cells or sickle cell precursors loaded with a therapeutic agent that localizes in tumors and induces a tumoricidal response. | 2009-06-18 |
20090155232 | Neonatal human hepatocytes immortalized using tert and methods of their use - The present invention relates to the discovery of immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. The invention is also directed to a method of obtaining telomerase-immortalized neonatal human hepatocytes that exhibit phenotypic features of human hepatic progenitor cells. Furthermore, the instant invention describes methods of using the immortalized neonatal human hepatocytes in cellular therapies, toxicological studies, pharmacokinetic studies, metabolic studies, therapeutic gene delivery and for the production of fully differentiated hepatocytes. | 2009-06-18 |
20090155233 | METHOD FOR TREATING TUMOR USING IRRADIATED TUMOR CELL EXPRESSING HUMAN HEPATITIS B SURFACE ANTIGEN AND A PHARMACEUTICAL COMPOSITION COMPRISING THE TUMOR CELL - The present invention relates to a method for treating a tumor in mammals comprising administering tumor cells in a therapeutically effective amount, in which the tumor cells lose their proliferative function by irradiation, are genetically manipulated to express hepatitis B surface antigen and are the same as the tumor to be treated, and a pharmaceutical composition for treatment of a tumor comprising the tumor cells. | 2009-06-18 |
20090155234 | DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, MX1 - A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided. | 2009-06-18 |
20090155235 | AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN - The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component alternatively, can take the role of a drug. The patent further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The patent finally reveals suitable methods and favourable conditions for carrier manufacturing and application. | 2009-06-18 |
20090155236 | Peptide sequence for modulation of delta protein kinase c - A peptide identified from the annexin V protein sequence and having the ability to modulate the activity of delta protein kinase C (PKC) is described. The peptide and variants thereof bind to delta PKC and are effective to regulate delta PKC mediated cellular responses. In particular the annexin V peptide is able to inhibit protein-protein interaction with delta PKC, blocking intracellular translocation of delta PKC. Inhibition of delta PKC translocation confers protection to tissue at risk of exposure to ischemia or hypoxia or to reperfusion injury. | 2009-06-18 |
20090155237 | COMPOSITIONS AND METHODS FOR BONE STRENGTHENING - The invention relates to methods of increasing bone strength in an animal, preferably a mammal. In one aspect, the methods provided by the invention involve administering to the animal strontium and a phytase enzyme. In another aspect, methods are provided for treating or preventing osteoporosis in a subject, the method comprising administering to said individual a phytase enzyme and strontium. Also encompassed are animal feed compositions comprising a phytase enzyme and supplemental strontium and a dietary supplement composition for administration to a human, the composition comprising a phytase enzyme and supplemental strontium. | 2009-06-18 |
20090155238 | XYLANASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM - The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal β-1,4-xylosidic linkages or endo-β-1,4-ghicanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature. | 2009-06-18 |
20090155239 | Novel Protease, Microorganism Producing the Same, and Application Thereof - An object of the present invention are to provide a protease that is stable in a wide pH range from acidic to alkaline, and that has excellent thrombolytic activity; a protease-producing microorganism that produces the above protease; and a process for producing the protease. | 2009-06-18 |
20090155240 | DICHLOROACETATE IN COMBINATION WITH CLINICALLY HIGH LEVELS OF CARDIOPROTECTIVE OR HEMODYNAMIC DRUGS - The present invention provides compositions and methods for using cardioprotective or hemodynamic drugs in combination with dichloroacetate enabling usage of cardioprotective or hemodynamic drugs at concentrations higher than used in normal clinical practice without increasing deleterious side effects normally associated with the cardioprotective or hemodynamic drug, thereby conferring added clinical benefit. The present invention teaches administration of DCA with cardioprotective or hemodynamic drugs as an adjunct therapy thereby conferring added clinical benefit to clinically recommended protocols. | 2009-06-18 |
20090155241 | Prophylactic/therapeutic agent for cancer - A compound or its salt that inhibits the activity of a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1; a compound or its salt that inhibits the expression of a gene for the protein; an antisense polynucleotide comprising a nucleotide sequence complementary or substantially complementary to the nucleotide sequence of a polynucleotide encoding the protein or a partial peptide thereof or a part of the nucleotide sequence; an antibody against the protein; etc. are useful as preventive/therapeutic agents for cancer, apoptosis promoters for cancer cells, or the like. | 2009-06-18 |
20090155242 | MAMMALIAN GENES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 2009-06-18 |
20090155243 | NON-HUMAN MODEL OF AUTOIMMUNE DISEASE - The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular, the invention provides a method of producing a non-human mammal having age-related macular degeneration (AMD). The invention is also directed to non-human animals produced by the methods described herein. Methods of identifying an agent for use in inhibiting one or more pathological characteristics of retinal degeneration and/or AMD is also encompassed by the invention. Also provided is a method of treating AMD in an individual in need thereof comprising, administering to the individual an agent identified herein. | 2009-06-18 |
20090155244 | METHODS AND COMPOSITIONS FOR POXVIRUS A35R PROTEIN - The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus. | 2009-06-18 |
20090155245 | Treatment for Organ Regeneration with Combination of Drug and Biologics - Combination therapies of drugs and biologics for treatment of acute and chronic organ degeneration are disclosed. More specifically, the use of morphogens, stem cells, and anti-inflammatories or inhibitors for the renin-angiotensin-aldosterone system (RAAS) for the treatment of acute and chronic renal disease is disclosed. | 2009-06-18 |
20090155246 | Antibodies Specific For Soluble Amyloid Beta Peptide Protofibrils and Uses Thereof - The invention pertains to the development of antibodies that specifically bind amyloid beta protein (Abeta) in its protofibril conformation. The invention also comprises methods of using anti-Abeta protofibril antibodies to diagnose or treat Alzheimer's disease, Down's syndrome Lewybody dementia, vascular dementia, and other neurodegenerative disorders. Furthermore, the invention pertains to the use of anti-Abeta protofibril antibodies to screen and identify substances that will modulate protofibril activity or formation in vitro or in vivo. The invention also pertains to methods for synthesising pure Abeta protofibril antigens as well as to a method for stabilising Abeta protofibrils antigens as well as to a method for stabilising Abeta protofibrils. | 2009-06-18 |
20090155247 | Methods of Using Death Receptor Agonists and EGFR Inhibitors - Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and EGFR inhibitors to treat pathological conditions such as cancer are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with EGFR inhibitors, such as Tarceva™. | 2009-06-18 |
20090155248 | Antibodies to MT-SP1 serine protease - This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer. | 2009-06-18 |
20090155249 | HUMANIZED ANTIBODY IGG1 - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 2009-06-18 |
20090155250 | MONOCLONAL ANTIBODIES AGAINST ORTHOPOXVIRUSES - The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 2009-06-18 |
20090155251 | Polypeptide compounds for inhibiting angiogenesis and tumor growth - In certain embodiments, this present invention provides polypeptide compositions, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases. | 2009-06-18 |
20090155252 | CHIMERIC ANTI-VEGF-D ANTIBODIES AND HUMANIZED ANTI-VEGF-D ANTIBODIES AND METHODS OF USING SAME - The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject. | 2009-06-18 |
20090155253 | ANTI-CD20 ANTIBODIES AND FUSION PROTEINS THEROF AND METHODS OF USE - The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis. | 2009-06-18 |
20090155254 | Affinity Regions - The present invention provides a method for selecting from a collection of IgIV molecules, at least one IgIV molecule comprising an affinity region that is capable of interacting with a misfolded protein and/or with an epitope of a cross-β structure and/or with an epitope of a protein comprising a cross-β structure, said method comprising contacting a collection of IgIV molecules with a misfolded protein and/or with a cross-β structure and/or with a protein comprising a cross-β structure and collecting at least one IgIV molecule comprising an affinity region interacting with said misfolded protein and/or epitope. | 2009-06-18 |
20090155255 | CD23 BINDING MOLECULES AND METHODS OF USE THEREOF - The invention is based, at least in part, on the development of multivalent and stabilized forms of CD23 binding molecules and methods of use thereof for the treatment of immune cell disorders, including leukemias or lymphomas such as CLL. | 2009-06-18 |
20090155256 | Immunotherapy Regimes Dependent On APOE Status - The invention provides methods of immunotherapy of Alzheimer's and similar diseases in which the regime administered to a patient depends on the ApoE genotype of the patient. | 2009-06-18 |
20090155257 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF - The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases. | 2009-06-18 |
20090155258 | PEPTIDE-BASED PASSIVE IMMUNIZATION THERAPY FOR TREATMENT OF ATHEROSCLEROSIS - The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization. | 2009-06-18 |
20090155259 | EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS - The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab. | 2009-06-18 |
20090155260 | USE OF THYMOSIN ALPHA 1 FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin. | 2009-06-18 |
20090155261 | METHODS AND COMPOSITIONS FOR TREATMENT AND DIAGNOSIS OF ENCEPHALITIS OR EPILEPSY - This invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to an NR1 subunit of the NMDA receptor. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to an NR1 subunit of the NMDA receptor and treating a tumor associated with the disease. | 2009-06-18 |
20090155262 | Cytotoxicity mediation of cells evidencing surface expression of CD63 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 2009-06-18 |
20090155263 | Compositions and methods for the treatment of immune related diseases - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases. | 2009-06-18 |
20090155264 | Novel composition and methods for the treatment of psoriasis - The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of psoriasis. | 2009-06-18 |
20090155265 | METHOD FOR TREATING MULTIPLE MYELOMA USING 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE IN COMBINATION WITH ANTIBODIES - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2009-06-18 |
20090155266 | Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases - The present invention includes compositions and methods for the treatment of a Th2 mediated inflammatory disease, relating to inhibiting a VEGF. The invention further includes methods to identify new compounds for the treatment of a Th2 mediated inflammatory disease, including, but not limited to, asthma and the like. This is because the present invention demonstrates, for the first time, that expression of VEGF induces asthma-like phenotype and that inhibiting VEGF reverses the phenotype. Thus, the invention relates to the novel discovery that inhibiting VEGF treats and prevents an Th2 mediated inflammatory disease. | 2009-06-18 |
20090155267 | MOLECULE AND CHIMERIC MOLECULES THEREOF - The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule which comprises a C-type lectin or an EGF-like domain such as amphiregulin, CD209L, Langerin, L-selectin or chimeric molecules thereof comprising at least a portion of the protein molecule, such as amphiregulin-Fc, CD209L-Fc, Langerin S, Langerin L, Langerin L-FLAG, Langerin-Fc, L-selectin-Fc wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications. | 2009-06-18 |
20090155268 | Growth Factor Binding Constructs Materials and Methods - The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors. Soluble binding constructs able to bind vascular endothelial growth factors, platelet derived growth factors, and other ligands are provided. | 2009-06-18 |
20090155269 | Mesothelin antibody protein fusions and methods of use - The invention relates to fusion proteins comprising a stress protein fused with an engineered antibody or fragment that binds to mesothelin, or a stress protein fused with a biotin-binding protein in combination with a biotinylated engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising a stress protein fused with an antibody binding protein in combination with an engineered antibody or fragment that binds to mesothelin. The invention also relates to fusion proteins comprising an engineered antibody or fragment that binds specifically to mesothelin fused in frame with a biotin binding protein. The invention also provides fusion proteins comprising an engineered antibody or fragment, that binds to mesothelin, fused with an antibody binding protein. The invention also relates to methods of using fusion proteins of the invention to induce an immune response to mesothelin and to treat disease. | 2009-06-18 |
20090155270 | CASPASE INHIBITORS, ESPECIALLY CASPASE 3 INHIBITORS, FOR THE TREATMENT OF INFLUENZA - The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for identifying suitable active substances. | 2009-06-18 |
20090155271 | IL-17A AND IL-17F ANTAGONISTS AND METHODS OF USING THE SAME - The present invention relates antagonists of IL-17A and IL-17F. The antagonists of the invention are based on IL-17RC alone or on both IL-17RC and IL-17RA (“IL-17RC/IL-17RA”). Such antagonists serve to block, inhibit, reduce, antagonize or neutralize the activity of IL-17F, IL-17A, or both IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RA is a receptor for IL-17A and IL-17RC is a common receptor for both IL-17A and IL-17F. The present invention includes soluble IL-17A and IL-17F anatagonists, as well as methods for using the same. | 2009-06-18 |
20090155272 | Targeted pharmaceuticals and ligands - The disclosure pertains to pharmaceuticals, more specifically, to targeted diagnostic and therapeutic formulations and ligands thereof. Such methods and composition comprise antigens that are post-translationally modified compared to antigens found on a normal cell phenotype. Also provided are ligands that bind to such post-translationally modified antigens. | 2009-06-18 |
20090155273 | REMEDIES FOR INFLAMMATORY BOWEL DISEASES - Antibodies against AILIM (also called ICOS and 8F4) were found to significantly suppress the onset of inflammatory bowel diseases (especially Crohn's disease and colitis (ulcerative colitis and such)), and exhibit a significant therapeutic effect against inflammatory bowel diseases. | 2009-06-18 |
20090155274 | HUMAN ANTI-NGF NEUTRALIZING ANTIBODIES AS SELECTIVE NGF PATHWAY INHIBITORS - This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided. | 2009-06-18 |
20090155275 | MULTISPECIFIC EPITOPE BINDING PROTEINS AND USES THEREOF - The present invention relates to multispecific epitope binding proteins, methods of making, and uses thereof in the prevention, management, treatment or diagnosis of acute or chronic diseases. | 2009-06-18 |
20090155276 | NOVEL DKKL-1 Splice Product Modulators for Cancer Diagnosis and Therapy - The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers. | 2009-06-18 |
20090155277 | Use of immunesuppressant receptor - The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. | 2009-06-18 |
20090155278 | Claudins as Markers for Early Detection, Diagnosis, Prognosis and as Targets of Therapy for Breast and Metastatic Brain or Bone Cancer - Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of | 2009-06-18 |
20090155279 | Pseudomonas Aeruginosa Outer Membrane Protein PA5158 - An object of the present invention is to provide a protein or peptide antigen and an antibody against it, for use in the diagnosis, prevention, or treatment of diseases associated with | 2009-06-18 |
20090155280 | Immunoglobulin Cleavage Fragments as Disease Indicators and Compositions for Detecting and Binding Such - The invention relates to antibody compositions and use of the composition to detect disease processes associated with elaboration of proteases. The reagents are directed to assessing an IgG breakdown product that is the result of such proteolytic cleavage. The invention further relates to the use of a therapeutic immunospecific for IgG breakdown products retaining antigen binding but having lost effector functions. | 2009-06-18 |
20090155281 | METHODS OF USING ANTIBODIES THAT BIND BOTH BCMA AND TACI - Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor, and the B-cell maturation (BCMA) receptor. | 2009-06-18 |
20090155282 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 2009-06-18 |
20090155283 | Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 - The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1α and/or IL-1β) to the receptor but do not inhibit binding of IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand. | 2009-06-18 |
20090155284 | HGF-SF MONOCLONAL ANTIBODY COMBINATIONS - The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer. | 2009-06-18 |
20090155285 | TGF-BETA BINDING ANTIBODIES - The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-β1, TGF-β2, and TGF-β3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. | 2009-06-18 |